CERTIFICATE OF Applicant(s): R. Band	Docket No. 3479/US							
Application No. 09/849,683	Filing Date 05-04-2001	Examiner Dwayne C. Jones	Customer No. 26648	Group Art Unit 1614				
Invertion P Anethod of FEB 2 8 2005	Using COX-2 Inhibitors	In The Treatment and Prevention of O	ocular COX-2 Me	diated Disorders				
TADENARY CO								
I hereby certify that this Response to Office Action (9 pgs) and Return Receipt Postcard (Identify type of correspondence)								
is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on								
	02-24-2005 (Date)	_ ·		•				
		Angela D	. Smith					
		(Typed or Printed Name of Perso		lence)				
	Ungela D. Smith							
		(Signatufe of Person Mai	ung Corresponaence)					
		•						
	Note: Each pa	per must have its own certificate of mailing.						
		<i>,</i>						
			٠					

AMENDMENT TRANSMITTAL LETTER (Large Entity) Applicant(s): R. Bandyopadhyay						Docket No. 3479/US	
Application No. 09/849,683	Filing Date 05/04/2001	Examiner Dwayne C. Jones	L	Customer No 26648	. Group Art Un	it Confirmation No. 8928	
Invention: 1 FM whod of Using COX-2 Inhibitors In The Treatment and Prevention of Ocular COX-2 Mediated Disorders							
TA TRADE	H. Comments	COMMISSIONER FO	R PATEN	NTS:			
I ransmitted nerew	vith is an amendment in	n the above-identified apsimitted as shown below.		i .			
		CLAIMS AS AM					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER		RATE	ADDITIONAL FEE	
TOTAL CLAIMS	12 -	12 =		0 x	\$50.00	\$0.00	
INDEP. CLAIMS	1 -	1 =		0 x	\$200.00	\$0.00	
Multiple Dependen	nt Claims (check if appl	licable)		1.1.		\$0.00	
		TOTAL ADDITIONAL F	FEE FOR	THIS AMEN	NDMENT	\$0.00	
 No additional fee is required for amendment. □ Please charge Deposit Account No. in the amount of □ A check in the amount of to cover the filing fee is enclosed. ☑ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 19-1025 ☑ Any additional filing fees required under 37 C.F.R. 1.16. ☑ Any patent application processing fees under 37 CFR 1.17. □ Payment by credit card. Form PTO-2038. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. 							
Philip B. Polster, II/ Reg. No. 43,864 Pharmacia Corporation P.O. Box 1027 St. Louis, MO 63006 CC:				I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on 2-24-05 (Date) Signatury of Person Mailing Correspondence Angela D. Smith			
 			Typed or Printed Name of Person Mailing Correspondence				



1614 grew

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	R. Bandyopadhyay) GROUP ART UNIT:	1614
SERIAL NO.:	09/849,683) CONFIRMATION NO.:	8928
EXAMINER:	Dwayne C. Jones)) ATTORNEY DOCKET	3479/US

FILED: 05/04/2001)

TITLE: METHOD OF USING COX-2 INHIBITORS IN THE TREATMENT

AND PREVENTION OF OCULAR COX-2 MEDIATED DISORDERS

NO.:

CERTIFICATE OF MAILING

I hereby certify that this communication and any recited enclosures are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 24, 2005.

Angela D. Smith

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO OFFICE ACTION

Sir:

This letter is in response to the Office Action of February 9, 2005, having a Shortened Statutory Period for Response that is set to expire on May 9, 2005. The Applicants believe that this response is timely filed, however, please charge any appropriate fees to Deposit Account No 19-1025.

(3479/1)

Claims are listed beginning on page 3 of this paper. **Remarks/Arguments** begin on page 6 of this paper.